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Purpose: Endobiliary stents can be used as surrogates for pancreatic
localization when using cone-beam computed tomography (CBCT)
during external-beam radiotherapy (EBRT). This work reports on
interfraction stent position changes during EBRT for locally
advanced pancreatic cancer (LAPC).
Materials and Methods: Six patients with endobiliary stents who
underwent EBRT for LAPC were assessed. Measurements from the
most superior aspect of the stent (sup stent) and the most inferior
aspect of the stent (inf stent) to the most inferior, posterior aspect
of the L1 vertebra central spinous process were determined from
daily treatment CBCTs and compared with those determined
from the planning computed tomography (CT) scan. Changes in
stent-L1 measurements were interpreted as changes in relative stent
position.
Results: Three patients showed mean interfraction stent position
changes of 1 cm when treatment measurements were
compared with planning measurements. The sup stent for patient A
moved to the right (2.66  2.77 cm) and inferiorly (3.0  3.12 cm),
and the inf stent moved to the right (1.92  2.02 cm)
inferiorly (3.23  3.34 cm) and posteriorly (1.41  1.43 cm).
The inf stent for patient B moved superiorly (2.23  0.49 cm) and
posteriorly (1.72  0.59 cm). The sup and inf stent for patient F moved
inferiorly (0.98  0.35 cm and 1.21  0.38 cm, respectively). The
remaining three patients C, D, and E showed interfraction position changes
of<1 cm.
Conclusion: Endobiliary stent migration and deformation were
observed in a small subset of patients. Further investigation is
required before confirming their use as surrogates for LAPC target
localization during image-guided EBRT.* Corresponding author: Kwun-Ye Chu, MSc, C/O Oxford University Hospitals N
OX3 7LE, United Kingdom. Tel.: 01865235465; fax: 01865235867.
E-mail address: kwun-ye.chu@oncology.ox.ac.uk (K.-Y. Chu).
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But : L’endoprothese endobiliaire peut e^tre utilisee substitut a la local-
isation pancreatique dans l’utilisation de la tomographie par ordinateura
faisceau conique (TOFC) en radiotherapie externe. La presente etude
faitetat du deplacement interfraction de l’endoprothese durant la radio-
therapie externe pour le cancer du pancreas localement avance (CPLA).
Materiel et methodologie : Six patients porteurs d’une
endoprothese endobiliaire ayant rec¸u des traitements de radiothera-
pie externe pour un CPLA ont ete evalues. Les mesures pour l’aspect
le plus superieur de l’endoprothese (sup stent) et son aspect le plus
inferieur (inf stent) par rapport a l’aspect le plus superieur et inferieur
de l’apophyse epineuse centrale de la vertebre L1 ont ete determines a
partir des traitements quotidiens de TOFC et compares a celles
etablies lors de la tomographie de planification. Les changements
dans la mesure endoprothese-L1 ont ete interpretes comme des
changements dans la position relative de l’endoprothese.
Resultats : Trois patients ont presente un deplacement interfraction de
l’endoprothese de 1 cm lorsque les mesures de traitement ont ete
comparees aux mesures de planification. Pour le patient A, la mesure
sup stent montre un deplacement vers la droite (2,662,77 cm) et le
bas (3,03,12 cm), tandis que lamesure inf stent se deplac¸ait vers la droite
(1,922,02 cm), le bas (3,233,34 cm) et l’arriere (1,411,43 cm). La
mesure inf stent pour le patient B montre un deplacement vers le haut
(2,230,49 cm) et l’arriere (1,720,59 cm). Les mesures sup et inf stent
du patient F montrent un deplacement vers le bas (0,980,35 cm et
1,210,38 cm, respectivement). Chez les trois autres patients (C, D et
E), le deplacement interfraction est inferieur a 1 cm.
Conclusion : La migration et la deformation de l’endoprothese
endobiliaire ont ete observees chez un petit sous-ensemble de
patients. D’autres etudes seront necessaires avant de pouvoir
confirmer leur utilisation comme substitut a la localisation des cibles
CPLA durant la radiotherapie externe guidee par l’image.Keywords: Stent; position change; image-guided radiotherapy; cone-beam CT; pancreatic cancerHS Trust, Radiotherapy Department, Churchill Hospital, Old Road, Oxford,
Introduction
The prognosis for patients diagnosed with pancreatic cancer is
poor. The 5-year survival rate in England for men and women
diagnosed with pancreatic cancer is 3.9% and 4.4%,
respectively [1]. For those with pancreatic tumours deemed
surgically unresectable with no distant metastases, their
disease is classified as locally advanced pancreatic cancer
(LAPC) [2]. Chemotherapy alone or chemoradiotherapy
may be used to treat patients with LAPC [3]. It is possible
to treat LAPC with either conformal radiotherapy or
intensity-modulated radiotherapy [4] though the presence of
several critical organs near the pancreas (eg, spinal cord,
kidneys, liver, and bowel) makes the planning and delivery
of radiotherapy complex, especially if nodal volume inclusion
creates a larger planning target volume (PTV) [5].
Image-guided radiotherapy (IGRT) can be used to ensure
treatment accuracy during radiotherapy treatments and limit
toxicity to organs at risk. While IGRT using megavolt
(MV) or kilovolt (kV) planar images can enhance accuracy,
these images provide mostly bony anatomy information
with minimal soft tissue definition [6]. Using bony anatomy
to align organs such as the pancreas has proven to be a poor
predictor of pancreatic location [7]. Cone-beam computed
tomography (CBCT) can provide additional soft tissue
definition, but delineating the pancreas and pancreatic
tumours on CBCT remains difficult. The lack of soft tissue
definition is likely caused by abdominal organ mobility [8].
Although Feng et al [9] found that the abdominal wall and
diaphragm were unsuitable surrogates for pancreatic tumour
position, this has not excluded the use of other internal
structures as surrogates. Studies have sought to use
fiducial markers [10], surgical clips [11], electromagnetic
transponders [12], and endobiliary stents [13] as pancreatic
tumour surrogates to assist with image matching.
Endobiliary stents are commonly implanted in pancreatic
cancer patients as a palliative measure to relieve symptoms
associated with biliary strictures such as jaundice [14], thereby
aiding chemoradiotherapy tolerability [2]. As the common
biliary duct runs through the pancreatic head, using an endo-
biliary stent as a surrogate for pancreatic localization can serve
as a potential alternative to the implantation of fiducial
markers, which are placed percutaneously under radiographic
guidance, intraoperatively, or using endoscopic ultrasound
[15]. Fiducial marker insertion for IGRT use would be an
additional procedure for patients with endobiliary stents
already inserted for palliative purposes. It is also unknown
how fiducial marker visibility may be affected if a stent is in
place as well. Endobiliary stents can be visualized on
CBCT, and it has been suggested that they can be used as a
surrogate when determining pancreatic tumour positions
[13]. Two studies have reported on CBCT-determined inter-
fraction motion of endobiliary stents during external-beam
radiotherapy (EBRT) and found minimal stent position
changes (<1 cm) with no indication of stent migration [11, 13].
In contrast, Johanson et al [16] reported stent migration rates58 K.-Y. Chu et al./Journal of Medical Imaging aof 4.9% proximally and 5.9% distally in the general patient
population. The work presented here seeks to report on the
stability of endobiliary stents in patients who received
chemoradiotherapy at our centre.
Patients and MethodsPatientsThe patients included in this retrospective study had previ-
ously provided informed consent for treatment on a research
ethics board–approved phase II trial conducted in accordance
with the Helsinki Declaration of 1964 and its later amend-
ments, examining the effects of a novel radiosensitizer nelfinavir
in combination with chemoradiotherapy in patients with LAPC
between October 2010 and September 2012. All trial patients
with an endobiliary stent implanted at the time of their plan-
ning computed tomography (CT) scan who underwent daily
CBCTs during their radiotherapy treatments were included in
this analysis. Six patients satisfied the inclusion criteria.Radiotherapy PlanningPatients received 59.4 Gy in 33 fractions prescribed with con-
current chemoradiation and nelfinavir. Treatment was planned
in the supine position with patients’ hands above their head,
arms and head supported by a vacuum bag, and knees supported
by a Kneefix (Civco Medical Systems, Kalona, IA). Planning
CTs were captured during exhale breath-hold with a 16-slice
helical CT scanner (GE Optima kV120, Smart mA, 0.25-cm
slices; GE Healthcare, Little Chalfont, UK). At planning,
patients also underwent fluoroscopy using a conventional
simulator (Varian Medical Systems, Palo Alto, CA) or a
4-dimensional CT (4DCT) using the CT scanner with the stent
visualized for breathing motion assessment. Breathing motion
data collected during planning was used to establish a stent
internal target volume contour for use in image matching. Gross
tumour volumes (GTVs) and clinical tumour volumes (CTVs)
were contoured on the planning CT by a radiation oncologist
using commercially available radiotherapy contouring
software (Varian Eclipse 10.0; Varian Medical Systems, Palo
Alto, CA). Phase 1 consisted of 50.4 Gy prescribed to PTV1
(¼ PTV_Oxford using the Oxford contouring method as
previously described by Fokas et al [5]), and phase 2 consisted
of 9 Gy prescribed to PTV2 (¼ GTV þ 1 cm superiorly,
2 cm inferiorly, and 1.5 cm circumferentially). For each phase,
3-dimensional conformal radiotherapy plans were delivered
using a combination of 6-MV and 15-MV beam energies.
Beam arrangements were individualized depending on tumour
location in relation to normal tissue with up to 7 coplanar
and noncoplanar beam angles.Daily Image GuidanceDaily treatment CBCTs (21EX Clinac 110 kV, 20 mA,
20 ms, 360/min, Varian Medical Systems) were captured dur-
ing free breathing to assess patient position and tumour
displacement. The treating radiation therapists compared thend Radiation Sciences 46 (2015) 57-64
daily treatment CBCTs with the planning CT online using
commercially available radiotherapy imaging software (Varian
On-Board Imager, Varian Medical Systems) to determine
displacement prior to treatment. As tumour definition was
difficult to assess on the treatment CBCTs, the endobiliary
stent, bony anatomy, and adjacent soft tissue structures (ie,
organs and vasculature) were used as surrogates for the tumour.
If displacement was greater than 0.3 cm in the right-left, supe-
rior-inferior, or anterior-posterior direction or if rotation was
greater than 3, then corrective action was taken and a repeat
CBCT was acquired. If displacement was less than 0.3 cm
and if rotation was less than 3, then treatment proceeded.Definition of Stent CharacteristicsFor this retrospective study, three points were identified on
all available planning CTs and treatment CBCT scans for
each patient: the most superior aspect of the stent (sup stent);
the most inferior aspect of the stent (inf stent); and the most
inferior, posterior aspect of the L1 vertebra central spinous
process (L1). Using contouring software, a digital marker
was placed at these points for each planning CT and
treatment CBCT (Figure 1). A specific set of x, y, and z
coordinates were associated with each marker; x corresponded
to the right(þ)/left() direction, y corresponded to the
superior(þ)/inferior() direction, and z corresponded to the
anterior(þ)/posterior() direction. All observations were
made by a single radiation therapist with several years of
experience in CBCT assessment. To determine intrauser
variability, the stent and L1 marker placements were repeated
on three separate occasions for the first five fractions.
Stent type (metal or plastic) was determined visually using
the planningCT. Stent lengthwas approximated by subtracting
the inf stent y coordinate from the sup stent y coordinate fromFigure 1. Placement of the sup stent measurement point on planning CT and day 10
images show axial views of the planning CT and day 10 CBCT, respectively. The top
CT and day 10 CBCT, respectively. Digital markers were placed at the most superio
stent position from the planning CT, and the red marker shows the sup stent positio
vertebra were placed on all available images, and the x, y, and z coordinates for these
K.-Y. Chu et al./Journal of Medical Imaging athe planning CT. Respiratory stent motion was determined
using the planning 4DCT or fluoroscopy. Virtual markers
were placed at the sup stent on the images associated with
maximum inhale and exhale, and the distance between these
markers were measured in the superior-inferior direction to
estimate the planning stent breathing motion.
Daily treatment stent-to-L1 (stent-L1) measurements were
determined using the daily CBCTs taken immediately before
treatment delivery. The distance between the sup stent and
the L1 vertebra was calculated by subtracting the L1
coordinates from the sup stent coordinates (sup-L1). The
distance between the inf stent and the L1 vertebra was
calculated by subtracting the L1 coordinates from the inf stent
coordinates (inf-L1). Changes in stent-L1 measurements were
interpreted as stent position changes. Limited soft tissue
definition on CBCT necessitated the comparison of surrogate
motion with a bony match as in previous studies [7, 13].
Once the sup-L1 and inf-L1 measurements were obtained for
each CBCT and planning CT, the planning stent-L1
measurements were then subtracted from the treatment
stent-L1 measurements to determine the interfraction stent
position relative to the baseline planning CT for both the sup
stent and the inf stent. The mean, median, maximum,
minimum, and interquartile range of interfraction stent
motion was calculated using commercially available statistics
software (IBM SPSS Statistics 20.0; IBM Corp, Armonk, NY).
Point-based analysis was performed to facilitate compari-
son with previous studies that examined interfraction stent
position change using motion analysis of a single point (single
end of stent [11] or centre of mass [13]). Because two points
at opposing ends of the stent were used to determine position
change for this study, any rotational error was captured as
oppositional movement of the two stent ends. Also, sinceCBCT to show stent position change. The far left (A1) and middle left (A2)
right (B1) and bottom right (B2) images show coronal views of the planning
r end of the stent using contouring software. The green marker shows the sup
n from the day 10 CBCT. Digital markers for the sup stent, inf stent, and L1
were used to determine the distances from the stent ends to the L1 vertebra.
nd Radiation Sciences 46 (2015) 57-64 59
Table 1
Patient Details Established from Planning
Patient Sex Age
(y)
Tumour
Location
Gross Tumour
Volume (cm3)
Stent
Type
Stent
Length (cm)
Sup Stent to L1 Distance
 Y Component (cm)
Planning Stent Sup-to-Inf
Breathing Motion (cm)
A Male 65 Head 27.78 Plastic 7.76 5.59 1.15
B Female 64 Head 41.10 Metal 10.10 6.09 1.87
C Female 60 Head 6.45 Plastic 6.81 6.41 1.41
D Female 63 Head 28.62 Plastic 9.21 2.71 Not available
E.1 Female 66 Head 19.33 Plastic 8.95 6.96 0.92
E.2 Female 66 Head Not contoured Plastic 8.91 8.52 Not available
F Female 62 Head 14.00 Metal 9.69 9.23 0.53
Inf, inferior; Sup, superior.endobiliary stents are flexible structures making assessment of
rotation alone difficult, using two points of measurement
accounted for both potential rotation and potential
deformation.Table 2
Interfraction Stent Position Change
Patient x (cm) y (cm) z (cm)
Sup-L1 Inf-L1 Sup-L1 Inf-L1 Sup-L1 Inf-L1
A Max 4.00 3.42 0.50 0.08 0.95 0.09
Min 0.49 0.95 4.16 4.34 0.92 2.06
Mean 2.66 1.92 3.00 3.23 0.43 1.41
SD 2.77 2.02 3.12 3.34 0.48 1.43
B Max 1.28 0.85 0.84 3.1 0.71 0.73
Min 0.95 2.12 0.92 1.37 0.96 3.34
Mean 0.06 0.61 0.08 2.23 0.37 1.72
SD 0.48 0.70 0.39 0.49 0.38 0.59
C Max 0.26 0.83 1.61 0.75 0.66 0.94
Min 1.36 0.69 0.01 0.90 0.53 0.37
Mean 0.64 0.29 0.71 0.10 0.13 0.16
SD 0.47 0.33 0.37 0.40 0.24 0.27
D Max 0.94 0.72 1.25 1.14 0.27 0.98
Min 0.42 0.37 0.21 0.27 0.77 0.01
Mean 0.23 0.20 0.54 0.42 0.22 0.52
SD 0.29 0.28 0.28 0.31 0.26 0.22
E.1 Max 1.76 0.68 0.60 0.34 0.17 0.14
Min 0.15 1.50 0.60 1.74 0.55 1.15Results
Patient details can be found in Table 1. Six patients
accrued from October 2010 to September 2012 were
included in this study (A, B, C, D, E, and F) with a mean
age of 63 years (range, 60–65 years) and a median GTV of
19.33 cm3 (range, 6.45 cm3–41.10 cm3). All LAPC masses
were located in the pancreatic head.
CBCTs were acquired for all patients for all 33 radio-
therapy fractions with 198 CBCTs acquired immediately
prior to treatment delivery. Three CBCTs were excluded
because of software issues and a stent reinsertion, leaving
195 CBCTs suitable for stent position analysis. For patient
A, CBCTs acquired on fractions 9 and 19 could not be
analysed using the contouring software, leaving 31 fractions
available for analysis. Six patients were included in the stent
position analysis but assessed as seven (A, B, C, D, E.1,
E.2, and F) because one patient required a stent reinsertion.
Patient E required a stent reinsertion on fraction 15 as stent
patency failure was suspected. Therefore, fraction 15 was
omitted from analysis and fractions 1–14 (patient E.1) were
analysed separately from 16–33 (patient E.2). The initial
planning CT provided the baseline stent information for
patient E.1, and a repeat CT scan taken at fraction 15 after
stent reinsertion provided the baseline stent information for
patient E.2 (Table 1).Mean 0.86 0.30 0.04 0.73 0.22 0.63
SD 0.49 0.66 0.32 0.50 0.20 0.34
E.2 Max 0.26 1.40 0.12 0.02 0.77 0.75Changes in Stent Position
Min 0.56 0.08 0.91 0.84 0.66 0.20
Mean 0.28 0.85 0.41 0.40 0.02 0.43
SD 0.21 0.36 0.23 0.20 0.32 0.15
F Max 0.83 0.91 0.20 0.30 0.52 1.18
Min 0.23 0.95 1.68 1.92 0.51 0.20
Mean 0.33 0.04 0.98 1.21 0.11 0.48
SD 0.27 0.40 0.35 0.38 0.23 0.35
All patients
Mean of means 0.44 0.33 0.45 0.43 0.09 0.31
SD of means 1.09 0.84 1.26 1.66 0.26 0.95
Inf, inferior; Max, maximum; Min, minimum; SD, standard deviation;
Sup, superior.Of the six patients assessed, three patients (A, B, and F)
exhibited pronounced and sustained stent position changes as
determined by examining the individual mean position change
for each patient in each direction (Table 2) and by visualizing
position change graphically over time (Figure 2). Patient A
showed sustained stent position changes with the sup stent
moving to the right (2.66  2.77 cm) and inferiorly
(3.0  3.12 cm) and the inf stent moving to the right
(1.92  2.02 cm) inferiorly (3.233.34 cm) and posteriorly
(1.41  1.43 cm). Patient B showed sustained stent position60 K.-Y. Chu et al./Journal of Medical Imaging achanges with the inf stent moving superiorly (2.23  0.49 cm)
and posteriorly (1.72  0.59 cm). Patient F showed sus-
tained stent position changes with both the sup and inf stent
moving inferiorly (0.98  0.35 cm and 1.21  0.38 cm,
respectively). The sustained position change was apparent
from the start of treatment for patients B and F but did not
become apparent in patient A until after fraction 5
(Figure 2). The degree of position change did not appear to
increase with time. The free-breathing superior-inferior stentnd Radiation Sciences 46 (2015) 57-64
Figure 2. Stent position changes as shown by the difference when the planned stent-L1 distance is subtracted from the daily treatment stent-L1 distance.motion determined from planning for patients A, B, and F
were 1.15 cm, 1.87 cm, and 0.53 cm, respectively (Table 1).
Although the sup and inf stent for patient A and F moved simi-
larly during treatment, only the inf stent for patient B showedFigure 3. Interfraction stent position relative to the baseline planning CT stent positi
outlier maximums and minimums represented by whiskers, interquartile ranges rep
intersecting the interquartile ranges.
K.-Y. Chu et al./Journal of Medical Imaging asustained position changes (Figures 2 and 3). The population
mean position change (mx,y,z) (ie, the mean of all patients’
individual means of position change) for the sup stent was
mx¼ 0.44  1.09 cm, my ¼ 0.45  1.26 cm, andon along the y-axis. Box plots with outliers represented by +’s andB’s, non-
resented by gray rectangles, and median values represented as horizontal lines
nd Radiation Sciences 46 (2015) 57-64 61
mz ¼ 0.09  0.26 cm. The population mean position change
for the inf stent for all patients was mx¼ 0.33  0.84 cm,
my¼ 0.43  1.65 cm, and mz ¼ 0.31  0.95 cm.
The standard deviation of position change (s) exhibited by
the inf stent was greater than that exhibited by the sup stent
(Table 2). For the y component of the stent-L1 distance, six
patients (B, C, D, E.1, E.2, and F) had sinf stent> ssup stent.
For the z component of the stent-L1 distance, five patients
(A, B, C, E.1, and F) had sinf stent> ssup stent. Repeat stent
measurements indicated minimal intrauser variability.Discussion
This study shows that the position of endobiliary stents can
vary greatly over the course of EBRT for LAPC in six patients.
Utilizing endobiliary stents as imaging surrogates for pancre-
atic tumours should be done cautiously as these stents may
lack positional stability during EBRT. In this study, three
patients exhibited sustained stent position changes from their
planning CT. We saw a greater rate of stent migration than
previously published by Johanson et al [16], which may be
evidence of distal stent migration only. The migration rate
differential may be related to study population selection as
Johanson’s sample consisted of a generalized patient
population that received endobiliary stents [16], whereas
this study had pancreatic cancer patients that received stents
prior to chemoradiotherapy.
It is unknown how the presence of malignancy,
chemotherapy, or EBRT affected stent migration incidence
in this study, but the development of radiotherapy-induced
pancreatic fibrosis may play a role. While malignancy and
chemotherapy may have influenced stent migration, Lofts
et al [17] found that cancer patients on a chemo-regime of
epirubicin, cisplatin, and 5-fluorouracil did not have a
significant increase in stent blockage or shortening of stent
patency duration. Significant interfraction deformation of
the pancreatic head, duodenum, and stomach can occur
during pancreatic head irradiation [18], and these inter-
fraction anatomic changes may affect stent migration.
Stent migration could be attributed to pancreatic irradia-
tion; however, other studies have found that endobiliary stents
were stable during radiotherapy [13, 19]. Zhu et al [19] found
no incidence of stent migration when they treated biliary
malignancy with intraluminal radiotherapy, but this may be
due to their use of a stent-in-stent configuration. Engineer
et al [13] concluded that endobiliary stents were stable
tumour surrogates during EBRT after they found population
mean position changes of less than 0.4 cm in all directions
during EBRT. We found similar population mean position
changes when patients were analysed together (<0.5 cm),
but when patients were examined individually, three patients
exhibited individual mean interfraction motions of greater
than 1 cm in at least one direction, indicating stent migration
occurrence. This contradicts the findings of Whitfield et al
[11] who reported that their stent patients had individual
mean interfraction stent motions of less than 1 cm for all62 K.-Y. Chu et al./Journal of Medical Imaging adirections during EBRT. Previous studies that examined
CBCT-determined interfraction stent motion during EBRT
had small samples (three [11] and five patients [13]). Perhaps
with larger study sizes, more cases of stent migration would
have also presented themselves in these studies.
The more inferior stent position during treatment
CBCTs may be due to the planning CTs being captured
during exhale breath-hold and the daily CBCTs being
captured during free-breathing; the stents appeared inferior
on CBCTs because inhalation caused inferior pressure on
the diaphragm and abdominal contents. However, not all
patients showed more inferiorly positioned stents. Mean y
values for patients C and D hovered closely around the
planned value. The influence of variable inhale and exhale
lung volumes on stent position as seen on free-breathing
CBCTs is unknown. The majority of the free-breathing
cycle is spent in exhale breath position [20], which suggests
that stent appearance on free-breathing CBCT roughly
correlates with its appearance on exhale breath-hold CT.
The inferior stent position change exhibited by patients A
and F was larger than the sup-to-inf breathing motion
established during planning. Inhalation may not be the
only contributing factor to an inferior position change; distal
stent migration may have occurred. This cannot be stated
conclusively because 4DCT-determined pancreatic tumour
motion may not have good correlation with the range of
motion demonstrated during radiotherapy [21, 22]. Other
nonrespiratory physiological processes may impact on stent
position. To distinguish between interfraction motion and
intrafraction motion, more detailed treatment imaging
such as 4-dimensional CBCT could be used to determine
stent positions on respiratory-correlated CBCT projections
[23]. Exhale breath-hold CBCTs could also be used to
minimize the respiratory component of intrafraction motion
and facilitate correspondence with the exhale breath-hold
planning CT. Ideally, stent position would be compared to
the pancreas to monitor migration occurrence, but limited
soft tissue definition on CBCT necessitates the comparison
of surrogate motion with a bony match as in previous studies
[7, 13]. More accurate soft tissue imaging and further study
would be required to determine whether change in stent
position is representative of position change of the
pancreatic head.
Most patients had greater standard deviation of position
change exhibited by the inf stent than the sup stent. Greater
freedom of movement was associated with the inf stent in
the superior-inferior and anterior-posterior planes than the
sup stent. Sup stent motion was likely restricted by the
concentration, size, and rigidity of internal organs in
the upper abdomen. Generally, both ends moved in the
same direction.
In patient B, the magnitude and direction of position
change did not correspond for the sup stent and inf stent.
Stent deformation may have occurred. The cause of this is
unknown but may be a result of bowel filling changes from
planning to treatment or weight loss during treatment. Thend Radiation Sciences 46 (2015) 57-64
incidence of stent deformation reinforces the method of
selecting two position points on the stent. Previous studies
selected a single stent position point such as a single end of
stent or centre of mass [11, 13] to assess interfraction stent
motion and did not report on stent deformation. As two
points at opposing ends of the stent were used to determine
position change for this study, any rotational error was
captured as oppositional movement of the two stent ends.
Endobiliary stents are flexible structures, making the
assessment of rotation alone difficult. By using two points
of measurement, both potential rotation and potential
deformation could be accounted for.
Because patients were referred from a number of centres,
the patients had a variety of both metal and plastic stents in
place. Although the variation in stent type did not affect
visualization of the stent on CBCT nor did it affect the
results, a greater number of patients with both metal and
plastic stents are required to determine this statistically.
A limitation of this study was the small sample size, which
did not allow for more robust statistical analysis. There was
considerable diversity between the patients’ results as shown
by the large standard deviation of all patients’ means. Without
more statistical tests, it is difficult to say whether this diversity
would also be found in a larger group of patients. Additional
study patients would allow for the identification of possible
trends with regards to stent migration as well as enable better
extrapolation to the wider irradiated LAPC population. Other
limitations of this study were that the method and timing of
stent insertion were not controlled nor was the stent type.
With patients being referred for radiotherapy after stent
insertion, controlling the previously mentioned variables
will require forethought and coordination. Careful, consistent
stent selection and insertion could reduce or eliminate stent
migration. Shortening the time frame from stent insertion
to the start and completion of radiotherapy may also
reduce stent migration during treatment. For those
receiving short-course radiotherapy for pancreatic cancer
[24–26], the position of the endobiliary stent may be
stable during IGRT because of the shorter time span of
treatment. For those patients who may undergo long-course
radiotherapy with a pre-existing stent, it is worth investigating
whether these patients may require an additional procedure
to exchange for a more stable endobiliary stent or to
insert additional fiducials to facilitate image guidance during
EBRT.Conclusion
Through examination of daily treatment images, large
sustained endobiliary stent position changes were observed
in a small subset of patients during EBRT for LAPC,
indicating the occurrence of stent migration and deformation.
Further study is needed to determine whether change in stent
position is representative of position change of the pancreatic
head and tumour, and whether stents are appropriate for use
as tumour surrogates.K.-Y. Chu et al./Journal of Medical Imaging aAcknowledgements
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